AMPERSAND CAPITAL PARTNERS
[Ampersand](http://www.ampersandventures.com/) is a middle market private equity firm focused on investments in two core sectors: Healthcare and Industrial.
AMPERSAND CAPITAL PARTNERS
Social Links:
Industry:
Angel Investment Finance Financial Services Health Care Venture Capital
Founded:
1988-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Champlain Capital Partners LP.
A small and middle-market private equity fund focused on niche businesses in manufacturing
Correlation Ventures
Correlation Ventures finances early, seed, and later stage venture, and debt financing investments and is based in California.
Kapor Capital
Kapor Capital is an investment firm that invests in early-stage tech-enabled startups.
PCI Technologies
PCI Technologies is a private equity firm that focuses on merger, asset acquisition and stock exchange services for health care industries.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-08-30 | Luina Bio | Luina Bio acquired by Ampersand Capital Partners | N/A |
| 2022-08-25 | Phosphorex | Phosphorex acquired by Ampersand Capital Partners | N/A |
| 2021-01-05 | Genezen Laboratories | Genezen Laboratories acquired by Ampersand Capital Partners | N/A |
| 2020-09-21 | GeneWerk | GeneWerk acquired by Ampersand Capital Partners | N/A |
| 2020-09-21 | ALPCO Diagnostics | ALPCO Diagnostics acquired by Ampersand Capital Partners | N/A |
| 2019-05-29 | Vibalogics | Vibalogics acquired by Ampersand Capital Partners | N/A |
| 2018-11-19 | Pacific Biomarkers | Pacific Biomarkers acquired by Ampersand Capital Partners | N/A |
| 2018-09-04 | NEOMED-LABS | NEOMED-LABS acquired by Ampersand Capital Partners | N/A |
| 2015-06-18 | Gyros Protein Technologies | Gyros Protein Technologies acquired by Ampersand Capital Partners | N/A |
| 2005-09-20 | RadPharm | RadPharm acquired by Ampersand Capital Partners | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-23 | Sterling Medical Devices | Ampersand Capital Partners investment in Private Equity Round - Sterling Medical Devices | N/A |
| 2022-06-07 | AnaBios | Ampersand Capital Partners investment in Private Equity Round - AnaBios | 6.5 M USD |
| 2022-06-02 | Vernal Biosciences | Ampersand Capital Partners investment in Venture Round - Vernal Biosciences | 21 M USD |
| 2022-04-18 | Syft Technologies | Ampersand Capital Partners investment in Private Equity Round - Syft Technologies | N/A |
| 2022-03-01 | BioEcho Life Sciences | Ampersand Capital Partners investment in Private Equity Round - BioEcho Life Sciences | N/A |
| 2021-03-18 | Magritek Ltd | Ampersand Capital Partners investment in Private Equity Round - Magritek Ltd | N/A |
| 2021-03-08 | Arranta Bio | Ampersand Capital Partners investment in Series B - Arranta Bio | N/A |
| 2021-01-01 | Avista Pharma | Ampersand Capital Partners investment in Private Equity Round - Avista Pharma | N/A |
| 2021-01-01 | Brammer Bio | Ampersand Capital Partners investment in Private Equity Round - Brammer Bio | N/A |
| 2019-10-30 | Arranta Bio | Ampersand Capital Partners investment in Venture Round - Arranta Bio | 82 M USD |
More informations about "Ampersand Capital Partners" on Search Engine
Ampersand Capital Partners | LinkedIn
Wellesley, MA 20,953 followers. Accelerating Growth with Healthcare Entrepreneurs. View all 45 employees. About us. Founded in 1988, Ampersand is a middle-market private equity firm with $3...See details»
Ampersand Capital Partners - Investments, Portfolio & Company …
Nov 28, 2023 32. exits. Ampersand Capital Partners's most notable exits include Bioventus , Azurity Pharmaceuticals , and LakePharma. Ampersand Capital Partners …See details»
AnaBios Closes Financing with Ampersand Capital …
SAN DIEGO, CA – June 7, 2022 – AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to measure drug activity …See details»
AnaBios Closes Funding with Ampersand Capital Partners
SAN DIEGO, CA – June 7, 2022 – AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique …See details»
Genezen Secures $18.5 Million in Growth Equity to Expand Viral …
Nov 2, 2023 FISHERS, Ind. and BOSTON, Nov. 2, 2023 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization …See details»
Ampersand Capital Partners | The Org
Founded in 1988, Ampersand is a middle-market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the …See details»
Ampersand Capital Partners - Funding, Financials, Valuation
Ampersand Capital Partners has raised a total of $2.4B across 4 funds, their latest being Ampersand 2022 Limited Partnership. This fund was announced on Aug 22, 2022 and …See details»
Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO
WELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has …See details»
AnaBios Closes Financing With Ampersand Capital Partners
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research …See details»
Ampersand Capital Partners - Contacts, Employees, Board …
Ampersand Capital Partners. Connect to CRM. Summary Financials Investments People Technology Signals & News Similar Companies. Highlights. Employee Profiles 24. …See details»
Ampersand Capital Partners Acquires Specac, Ltd. - Specac Ltd
ORPINGTON, England, March 13, 2024 /PRNewswire/ — Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life …See details»
Julius Clinical Research Receives Growth Investment from …
Nov 28, 2023 Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented …See details»
Ampersand Capital Partners Acquires Specac, Ltd. - Yahoo Finance
ORPINGTON, England, March 13, 2024 /PRNewswire/ -- Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life …See details»
Julius Clinical Research Receives Growth Investment from …
Nov 28, 2023 Michelle Heuvelmans. Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners. Partnership will further expand Julius’ clinical trial …See details»
Ampersand Capital Partners - Crunchbase Investor Profile
Ampersand is a middle market private equity firm that focuses on healthcare and industrial sectors. Wellesley, Massachusetts, United States. 11-50. Private Equity Firm. Debt, …See details»
Ampersand Capital Partners Acquires Specac, Ltd. - MarketWatch
Mar 13, 2024 Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented …See details»
Ampersand Capital Partners Acquires Specac, Ltd.
Orpington, UK, March 13th, 2024 – Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life sciences and healthcare …See details»
Biologos acquired by Ampersand Capital Partners - Crunchbase
Mar 19, 2024 Overview. Acquired Organization: Biologos Biologos is a full-service manufacturer of standard and custom cell culture media and reagents. Acquiring …See details»
Ampersand Capital Partners acquires Specac Ltd - Crunchbase
Announced Date Mar 13, 2024. Acquisition Type Acquisition. Acquisition Status Pending. Disposition of Acquired Organization Separate Entity. Unlock even more features with …See details»